Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Dow
Julphar
McKesson
Medtronic
Moodys
Mallinckrodt
Citi
Novartis
Johnson and Johnson

Generated: February 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,562,564

« Back to Dashboard

Which drugs does patent 8,562,564 protect, and when does it expire?

Patent 8,562,564 protects OTREXUP and is included in one NDA.

This patent has nine patent family members in eight countries.
Summary for Patent: 8,562,564
Title:Prefilled syringe jet injector
Abstract: A jet injector that includes a prefilled syringe. The syringe includes a fluid chamber that contains a medicament. The syringe also has an injection-assisting needle, and a plunger is movable within the fluid chamber. A housing is configured for allowing insertion of the needle to a penetration depth. An energy source is configured for biasing the plunger to produce an injecting pressure in the medicament in the fluid chamber of between about 80 and 1000 p.s.i. to jet inject the medicament from the fluid chamber through the needle to an injection site.
Inventor(s): Lesch, Jr.; Paul R. (Lino Lakes, MN)
Assignee: Antares Pharma, Inc. (Ewing, NJ)
Application Number:13/236,120
Patent Claim Types:
see list of patent claims
Dosage form; Delivery; Device;

Drugs Protected by US Patent 8,562,564

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-005 Nov 7, 2014 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-001 Oct 11, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-006 Mar 24, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-002 Oct 11, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-007 Mar 24, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-003 Oct 11, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-008 Mar 24, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-004 Oct 11, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,562,564

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,629,959 Prefilled syringe jet injector ➤ Sign Up
8,021,335 Prefilled syringe jet injector ➤ Sign Up
9,180,259 Prefilled syringe jet injector ➤ Sign Up
9,533,102 Prefilled syringe jet injector ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,562,564

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Korea 20070117543 ➤ Sign Up
Japan 5216328 ➤ Sign Up
Japan 2008528126 ➤ Sign Up
Israel 184765 ➤ Sign Up
European Patent Office 1850892 ➤ Sign Up
China 101132820 ➤ Sign Up
Canada 2595730 ➤ Sign Up
Brazil PI0614025 ➤ Sign Up
World Intellectual Property Organization (WIPO) 2006079064 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Citi
Cipla
Daiichi Sankyo
McKesson
Farmers Insurance
Colorcon
Queensland Health
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot